Cara Therapeutics Announces Biomarker Data from KALM-1 and KALM-2 Trials of KORSUVA™ (difelikefalin) Injection Selected for Presentation at National Kidney Foundation Spring Clinical Meetings 2022

Rhea-AI Summary

Cara Therapeutics (Nasdaq: CARA) announced the presentation of biomarker data from the KALM-1 and KALM-2 clinical trials for KORSUVA (difelikefalin) at the National Kidney Foundation Spring Clinical Meetings 2022. The poster highlights a reduction in itch intensity correlated with decreased inflammatory markers in patients with chronic kidney disease-associated pruritus undergoing hemodialysis. Presentations will take place on April 7, 2022, with additional posters addressing treatment effects on itch severity and sleep disruption. KORSUVA is the first FDA-approved treatment for this condition.

Positive

• Difelikefalin shows efficacy in reducing itch intensity in clinical trials.
• Correlates with reductions in inflammatory markers, indicating potential broader therapeutic effects.
• KORSUVA is the first FDA-approved treatment for moderate-to-severe pruritus in hemodialysis patients.

Negative

• None.

Poster highlights reduction in itch intensity with difelikefalin treatment correlated with reductions in inflammatory markers in patients with chronic kidney disease-associated pruritus undergoing hemodialysis

STAMFORD, Conn., April 04, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced biomarker data from the KALM-1 and KALM-2 clinical trials evaluating KORSUVA™ (difelikefalin) injection for the treatment of chronic kidney disease-associated pruritus in patients undergoing hemodialysis will be presented in a poster at the National Kidney Foundation Spring Clinical Meetings 2022 (SCM22), to be held April 6-10, 2022, in Boston, MA.

Details for the poster presentation are as follows:

Title: Reduction of Pruritus by Difelikefalin Correlates With Reductions in Markers for Pruritus and Inflammation in Subjects Undergoing Hemodialysis
Poster Number: 207
Date and Time: April 7, 2022, 6:00-7:30 p.m. ET
Presenter: Shayan Shirazian, MD, Columbia University College of Physicians and Surgeons, New York, NY

The ePoster is available at: https://www.kidney.org/spring-clinical.

In addition, details for other posters highlighting KORSUVA injection are as follows:

Title: Effect of Treatment with Difelikefalin on Itch Severity in Patients with Chronic Kidney Disease-Associated Pruritus Measured by the Patient Global Impression of Change
Poster Number: 212

Title: Improvement in Itch-Related Sleep Disruption with Difelikefalin in Patients with Moderate to Severe Chronic Kidney Disease Associated Pruritus Undergoing Hemodialysis: A Post-hoc Analysis of an Open-Label, Multicenter Study
Poster Number: 261

Title: CKD-associated Pruritus After 12 Weeks of Therapy with Difelikefalin Among Hemodialysis Patients with Severe Pruritus: A Post-hoc Analysis of Phase 3 Studies
Poster Number: 262

About Cara Therapeutics

Cara Therapeutics is an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s novel KORSUVA™ (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. Phase 2 trials of Oral KORSUVA (difelikefalin) are ongoing in primary biliary cholangitis and notalgia paresthetica patients with moderate-to-severe pruritus. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn and Instagram.

MEDIA CONTACT:
Annie Spinetta
6 Degrees
973-768-2170
aspinetta@6degreespr.com

INVESTOR CONTACT:
Iris Francesconi, Ph.D.
Cara Therapeutics
203-406-3700
investor@caratherapeutics.com

FAQ

What does the latest data reveal about KORSUVA (CARA) in chronic kidney disease?

The data shows that difelikefalin effectively reduces itch intensity correlated with lower inflammatory markers.

When will Cara Therapeutics present clinical trial data?

Data will be presented on April 7, 2022, at the National Kidney Foundation Spring Clinical Meetings.

What is the significance of the KALM-1 and KALM-2 trials for CARA?

These trials provide important data supporting the efficacy of KORSUVA as a treatment for pruritus in hemodialysis patients.

Is KORSUVA the first treatment of its kind for patients undergoing hemodialysis?

Yes, KORSUVA is the first FDA-approved treatment specifically for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis.